NCT03388619 2026-02-23
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
52 trialsNCT03995888 2026-02-12
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
Blue Earth Diagnostics
Phase 1 Completed
NCT03582475 2025-11-12
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03218826 2025-10-30
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03253744 2025-10-08
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03873805 2025-06-26
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04740034 2025-06-17
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
Amgen
Phase 1 Terminated
NCT04927663 2025-05-20
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
University of California, San Francisco
Phase 1 Terminated
NCT00328614 2025-05-16
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT03300505 2025-05-13
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT05332340 2025-03-07
Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
Biozeus Biopharmaceutical S.A.
Phase 1 Completed
NCT04428203 2025-03-05
Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
University of Kentucky
Phase 1 Completed
NCT03805594 2025-02-25
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT03436745 2025-02-11
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02555397 2024-10-10
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
Henry Ford Health System
Phase 1 Completed
NCT04672460 2024-09-25
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03276572 2024-06-13
Phase I Trial of 225Ac-J591 in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Completed
NCT04086966 2024-04-26
PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study
University of Alabama at Birmingham
Phase 1 Completed
NCT03822871 2024-03-21
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Cancer Targeted Technology
Phase 1 Completed
NCT02995330 2024-02-13
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT04803305 2024-01-12
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Pfizer
Phase 1 Completed
NCT02616185 2023-11-02
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Pfizer
Phase 1 Terminated
NCT03840200 2023-10-30
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Hoffmann-La Roche
Phase 1 Completed
NCT00292045 2023-10-04
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00623831 2022-10-25
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00972309 2022-10-12
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00199849 2022-10-10
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT03120832 2021-11-12
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
Sensei Biotherapeutics, Inc.
Phase 1 Completed
NCT03481816 2021-05-19
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03478904 2021-05-10
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02179515 2021-01-26
Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03384316 2020-09-09
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00702923 2019-11-21
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
University of Wisconsin, Madison
Phase 1 Terminated
NCT02500901 2019-10-21
Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
Hoosier Cancer Research Network
Phase 1 Terminated
NCT00510718 2019-10-03
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
Pfizer
Phase 1 Completed
NCT00124917 2019-09-13
Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01565928 2019-04-22
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
Pfizer
Phase 1 Completed
NCT02111187 2019-03-07
LDE225
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01286987 2019-01-10
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
Phase 1 Completed
NCT00822510 2018-05-11
Telephone Counseling: Men With Prostate Cancer & Partners
University of Arizona
Phase 1 Completed
NCT00958477 2017-08-02
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01642732 2017-05-30
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT01347788 2016-11-28
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT02093390 2016-06-06
A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT02057237 2015-12-17
A Safety and Feasibility Study of Mitotane in Prostate Cancer
University Health Network, Toronto
Phase 1 Completed
NCT00585637 2015-04-01
Vitamin D for Chemoprevention
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00753415 2015-03-17
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00441337 2015-02-20
MDX1106-01
Bristol-Myers Squibb
Phase 1 Completed
NCT00424385 2014-07-21
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Oncology Specialists, S.C.
Phase 1 Completed